{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:23:10Z","timestamp":1790792590153,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"SIDN fonds","award":["174054"],"award-info":[{"award-number":["174054"]}]},{"name":"SIDN fonds","award":["174054"],"award-info":[{"award-number":["174054"]}]},{"name":"SIDN fonds","award":["174054"],"award-info":[{"award-number":["174054"]}]},{"name":"SIDN fonds","award":["174054"],"award-info":[{"award-number":["174054"]}]},{"name":"SIDN fonds","award":["174054"],"award-info":[{"award-number":["174054"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current methods of pharmacovigilance result in severe under-reporting of adverse drug events (ADEs). Patient forums have the potential to complement current pharmacovigilance practices by providing real-time uncensored and unsolicited information. We are the first to explore the value of patient forums for rare cancers. To this end, we conduct a case study on a patient forum for Gastrointestinal Stromal Tumor patients. We have developed machine learning algorithms to automatically extract and aggregate side effects from messages on open online discussion forums. We show that patient forum data can provide suggestions for which ADEs impact quality of life the most: For many side effects the relative reporting rate differs decidedly from that of the registration trials, including for example cognitive impairment and alopecia as side effects of avapritinib. We also show that our methods can provide real-world data for long-term ADEs, such as osteoporosis and tremors for imatinib, and novel ADEs not found in registration trials, such as dry eyes and muscle cramping for imatinib. We thus posit that automated pharmacovigilance from patient forums can provide real-world data for ADEs and should be employed as input for medical hypotheses for rare cancers.<\/jats:p>","DOI":"10.1038\/s41598-022-13894-8","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T09:04:11Z","timestamp":1655715851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Automated gathering of real-world data from online patient forums can complement pharmacovigilance for rare cancers"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4332-0296","authenticated-orcid":false,"given":"Anne","family":"Dirkson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9609-9505","authenticated-orcid":false,"given":"Suzan","family":"Verberne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7797-619X","authenticated-orcid":false,"given":"Wessel","family":"Kraaij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"van Oortmerssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-8636","authenticated-orcid":false,"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"13894_CR1","unstructured":"World Health Organisation, The Safety of Medicines in Public Health Programmes: Pharmacovigilance an essential tool, 2006."},{"issue":"7","key":"13894_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40264-017-0530-5","volume":"40","author":"L Rolfes","year":"2017","unstructured":"Rolfes, L., van Hunsel, F., van der Linden, L., Taxis, K. & van Puijenbroek, E. The quality of clinical information in adverse drug reaction reports by patients and healthcare professionals: A retrospective comparative analysis. Drug Saf. 40(7), 607\u2013614 (2017).","journal-title":"Drug Saf."},{"issue":"4","key":"13894_CR3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4103\/2229-3485.167099","volume":"6","author":"P Shenoy","year":"2015","unstructured":"Shenoy, P. & Harugeri, A. Elderly patients\u2019 participation in clinical trials. Perspect. Clin. Res. 6(4), 184 (2015).","journal-title":"Perspect. Clin. Res."},{"key":"13894_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1136\/bmj.329.7456.44","volume":"329","author":"BH Stricker","year":"2004","unstructured":"Stricker, B. H. & Psaty, B. M. Detection, verification, and quantification of adverse drug reactions. BMJ 329, 44\u201347 (2004).","journal-title":"BMJ"},{"issue":"5","key":"13894_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell, L. & Shakir, S. A. W. Under-reporting of adverse drug reactions a systematic review. Drug Saf. 29(5), 385\u2013396 (2006).","journal-title":"Drug Saf."},{"issue":"8","key":"13894_CR6","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40264-016-0422-0","volume":"39","author":"L Rolfes","year":"2016","unstructured":"Rolfes, L., van Hunsel, F., Taxis, K. & van Puijenbroek, E. The impact of experiencing adverse drug reactions on the patient\u2019s quality of life: A retrospective cross-sectional study in the Netherlands. Drug Saf. 39(8), 769\u2013776 (2016).","journal-title":"Drug Saf."},{"issue":"6","key":"13894_CR7","doi-asserted-by":"publisher","first-page":"21864","DOI":"10.1136\/bmjopen-2018-021864","volume":"8","author":"K Plueschke","year":"2018","unstructured":"Plueschke, K., McGettigan, P., Pacurariu, A., Kurz, X. & Cave, A. EU-funded initiatives for real world evidence: Descriptive analysis of their characteristics and relevance for regulatory decision-making. BMJ Open 8(6), 21864 (2018).","journal-title":"BMJ Open"},{"issue":"6","key":"13894_CR8","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1177\/1932296819839996","volume":"13","author":"DC Klonoff","year":"2019","unstructured":"Klonoff, D. C., Gutierrez, A., Fleming, A. & Kerr, D. Real-world evidence should be used in regulatory decisions about new pharmaceutical and medical device products for diabetes. J. Diabetes Sci. Technol. 13(6), 995\u20131000 (2019).","journal-title":"J. Diabetes Sci. Technol."},{"key":"13894_CR9","unstructured":"Radawski, C. A. et al., The utility of real\u2010world evidence for benefit\u2010risk assessment, communication, and evaluation of pharmaceuticals: Case studies, Pharmacoepidemiol. Drug Saf., p. pds.5167 (2020)."},{"issue":"9","key":"13894_CR10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40264-020-00951-2","volume":"43","author":"B Audeh","year":"2020","unstructured":"Audeh, B., Bellet, F., Beyens, M. N., Lillo-Le Lou\u00ebt, A. & Bousquet, C. Use of social media for pharmacovigilance activities: Key findings and recommendations from the project. Drug Saf. 43(9), 835\u2013851 (2020).","journal-title":"Drug Saf."},{"key":"13894_CR11","doi-asserted-by":"crossref","unstructured":"S. Golder, K. Smith, K. O\u2019Connor, R. Gross, S. Hennessy, and G. Gonzalez-Hernandez, A comparative view of reported adverse effects of statins in social media, regulatory data, drug information databases and systematic reviews, Drug Saf., 1\u201313 (2020).","DOI":"10.1007\/s40264-020-00998-1"},{"key":"13894_CR12","doi-asserted-by":"crossref","unstructured":"S. Khosla et al., Real world evidence (RWE)\u2014a disruptive innovation or the quiet evolution of medical evidence generation?, F1000Research, 7, 111, 2018.","DOI":"10.12688\/f1000research.13585.1"},{"issue":"6","key":"13894_CR13","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/clpt.2012.50","volume":"91","author":"R Harpaz","year":"2012","unstructured":"Harpaz, R. et al. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin. Pharmacol. Ther. 91(6), 1010\u20131021 (2012).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"13894_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1046\/j.1365-2125.1999.00060.x","volume":"48","author":"IA Eland","year":"1999","unstructured":"Eland, I. A. et al. Attitudinal survey of voluntary reporting of adverse drug reactions. Br. J. Clin. Pharmacol. 48(4), 623\u2013627 (1999).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"13894_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jbi.2015.02.004","volume":"54","author":"A Sarker","year":"2015","unstructured":"Sarker, A. et al. Utilizing social media data for pharmacovigilance: A review. J. Biomed. Inform. 54, 202\u2013212 (2015).","journal-title":"J. Biomed. Inform."},{"issue":"2","key":"13894_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1037\/0003-066X.55.2.205","volume":"55","author":"KP Davison","year":"2000","unstructured":"Davison, K. P., Pennebaker, J. W. & Dickerson, S. S. Who talks? The social psychology of illness support groups. Am. Psychol. 55(2), 205\u2013217 (2000).","journal-title":"Am. Psychol."},{"issue":"4","key":"13894_CR17","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/bcp.12717","volume":"80","author":"R Sloane","year":"2015","unstructured":"Sloane, R. et al. Social media and pharmacovigilance: A review of the opportunities and challenges. Br. J. Clin. Pharmacol. 80(4), 910\u2013920 (2015).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9","key":"13894_CR18","doi-asserted-by":"publisher","DOI":"10.2196\/resprot.6463","volume":"6","author":"C Bousquet","year":"2017","unstructured":"Bousquet, C. et al. The adverse drug reactions from patient reports in social media project: Five major challenges to overcome to operationalize analysis and efficiently support pharmacovigilance process. JMIR Res. Protoc. 6(9), e179 (2017).","journal-title":"JMIR Res. Protoc."},{"key":"13894_CR19","doi-asserted-by":"crossref","unstructured":"Cesare, N., Grant, C. & Nsoesie, E. O. Understanding demographic bias and representation in social media health data, in WebSci 2019\u2014Companion of the 11th ACM Conference on Web Science, 2019, pp. 7\u20139.","DOI":"10.1145\/3328413.3328415"},{"issue":"4","key":"13894_CR20","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/bcp.12746","volume":"80","author":"S Golder","year":"2015","unstructured":"Golder, S., Norman, G. & Loke, Y. K. Systematic review on the prevalence, frequency and comparative value of adverse events data in social media. Br. J. Clin. Pharmacol. 80(4), 878\u2013888 (2015).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7","key":"13894_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2196\/jmir.4304","volume":"17","author":"J Lardon","year":"2015","unstructured":"Lardon, J. et al. Adverse drug reaction identification and extraction in social media: A scoping review. J. Med. Internet Res. 17(7), 1\u201316 (2015).","journal-title":"J. Med. Internet Res."},{"key":"13894_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","volume":"40","author":"K S\u00f8reide","year":"2016","unstructured":"S\u00f8reide, K. et al. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 40, 39\u201346 (2016).","journal-title":"Cancer Epidemiol."},{"key":"13894_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/978-94-017-2390-9_10","volume-title":"Natural language processing using very large corpora","author":"LA Ramshaw","year":"1999","unstructured":"Ramshaw, L. A. & Marcus, M. P. Text chunking using transformation-based learning. In Natural language processing using very large corpora (eds Armstrong, S. et al.) 157\u2013176 (Springer, 1999)."},{"key":"13894_CR24","unstructured":"U.S. National Library of Medicine, \u201cRxNorm.\u201d [Online]. Available: https:\/\/www.nlm.nih.gov\/research\/umls\/rxnorm\/."},{"key":"13894_CR25","unstructured":"A. Dirkson, S. Verberne, and W. Kraaij, \u201cNarrative Detection in Online Patient Communities,\u201d in Proceedings of the Text2StoryIR\u201919 Workshop, 2019."},{"key":"13894_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jbi.2015.03.010","volume":"55","author":"S Karimi","year":"2015","unstructured":"Karimi, S., Metke-Jimenez, A., Kemp, M. & Wang, C. Cadec: A corpus of adverse drug event annotations. J. Biomed. Inform. 55, 73\u201381 (2015).","journal-title":"J. Biomed. Inform."},{"key":"13894_CR27","doi-asserted-by":"crossref","unstructured":"Weissenbacher, D. et al., Overview of the Fourth Social Media Mining for Health (#SMM4H) Shared Task at ACL 2019, in Proceedings ofthe 4th Social Media Mining for Health Applications (#SMM4H) Workshop & Shared Task, 2019, pp. 21\u201330.","DOI":"10.18653\/v1\/W19-3203"},{"key":"13894_CR28","doi-asserted-by":"crossref","unstructured":"Basaldella, M., Liu, F., Shareghi, E., & Collier, N. COMETA: A Corpus for Medical Entity Linking in the Social Media, in Proceedings of the 2020 Conference on Empirical Methods in Natural Language Processing, 2020, pp. 3122\u20133137.","DOI":"10.18653\/v1\/2020.emnlp-main.253"},{"key":"13894_CR29","doi-asserted-by":"crossref","unstructured":"Zolnoori, M. et al., \u201cThe PsyTAR dataset: From patients generated narratives to a corpus of adverse drug events and effectiveness of psychiatric medications.,\u201d Data Br., vol. 24, Jun. 2019.","DOI":"10.1016\/j.dib.2019.103838"},{"issue":"12","key":"13894_CR30","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s40264-019-00858-7","volume":"42","author":"J van Stekelenborg","year":"2019","unstructured":"van Stekelenborg, J. et al. Recommendations for the Use of Social Media in Pharmacovigilance: Lessons from IMI WEB-RADR. Drug Saf. 42(12), 1393\u20131407 (2019).","journal-title":"Drug Saf."},{"key":"13894_CR31","unstructured":"FDA, \u201cFDA approves ripretinib for advanced gastrointestinal stromal tumor,\u201d 2020. [Online]. Available: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-ripretinib-advanced-gastrointestinal-stromal-tumor."},{"key":"13894_CR32","unstructured":"European Medicine Agency, \u201cAyvakyt,\u201d 2020. [Online]. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ayvakyt."},{"issue":"7","key":"13894_CR33","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri, G. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347(7), 472\u2013480 (2002).","journal-title":"N. Engl. J. Med."},{"issue":"9440","key":"13894_CR34","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","volume":"364","author":"J Verweij","year":"2004","unstructured":"Verweij, J. et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364(9440), 1127\u20131134 (2004).","journal-title":"Lancet"},{"issue":"4","key":"13894_CR35","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke, C. D. et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol. 26(4), 626\u2013632 (2008).","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"13894_CR36","first-page":"3034","volume":"8","author":"R Dagher","year":"2002","unstructured":"Dagher, R. et al. Approval summary: imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res. 8(10), 3034\u20133038 (2002).","journal-title":"Clin. Cancer Res."},{"key":"13894_CR37","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1159\/000487511","volume":"41","author":"P Reichardt","year":"2018","unstructured":"Reichardt, P. The story of imatinib in GIST-a journey through the development of a targeted therapy. Oncol. Res. Treat 41, 472\u2013477 (2018).","journal-title":"Oncol. Res. Treat"},{"key":"13894_CR38","unstructured":"U.S. Food and Drug Administration (FDA), \u201cGLEEVEC (imatinib mesylate) tablets Label.\u201d [Online]. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021588s024lbl.pdf."},{"issue":"9544","key":"13894_CR39","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri, G. D. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368(9544), 1329\u20131338 (2006).","journal-title":"Lancet"},{"key":"13894_CR40","unstructured":"U.S. Food and Drug Administration (FDA), \u201cSUTENT (sunitinib malate) capsules label.\u201d [Online]. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021938s13s17s18lbl.pdf."},{"issue":"9863","key":"13894_CR41","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri, G. D. et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863), 295\u2013302 (2013).","journal-title":"Lancet"},{"key":"13894_CR42","unstructured":"U.S. Food and Drug Administration (FDA), \u201cSTIVARGA (regorafenib) tablets label.\u201d [Online]. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203085s007lbl.pdf."},{"key":"13894_CR43","unstructured":"E. M. Agency, Summary of Product Characteristics Imatinib. [Online]. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/glivec-epar-product-information_en.pdf."},{"key":"13894_CR44","unstructured":"World Health Organization, The Importance of Pharmacovigilance: Safety Monitoring of medicinal products, Geneva, 2002."},{"key":"13894_CR45","unstructured":"European Medicine Agency, Guideline on good pharmacovigilance practices (GVP) - Annex I - Definitions (Rev 4), 2017."},{"key":"13894_CR46","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1016\/S0140-6736(08)60875-2","volume":"371","author":"S Aym\u00e9","year":"2008","unstructured":"Aym\u00e9, S., Kole, A. & Groft, S. Empowerment of patients: Lessons from the rare diseases community. Lancet 371, 2048\u20132051 (2008).","journal-title":"Lancet"},{"issue":"23\u201324","key":"13894_CR47","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.drudis.2009.09.008","volume":"14","author":"HE Heemstra","year":"2009","unstructured":"Heemstra, H. E., van Weely, S., B\u00fcller, H. A., Leufkens, H. G. M. & de Vrueh, R. L. A. Translation of rare disease research into orphan drug development: Disease matters. Drug Discov. Today 14(23\u201324), 1166\u20131173 (2009).","journal-title":"Drug Discov. Today"},{"key":"13894_CR48","unstructured":"U.S Congress Office of Technology Assessment, Pharmaceutical R\\&D: Costs, Risks, and Rewards. Washington, DC: U.S. Government Printing Office, 1993."},{"issue":"1","key":"13894_CR49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000484102","volume":"97","author":"K Ogata","year":"2018","unstructured":"Ogata, K. et al. Long-term imatinib treatment for patients with unresectable or recurrent gastrointestinal stromal tumors. Digestion 97(1), 20\u201325 (2018).","journal-title":"Digestion"},{"issue":"15","key":"13894_CR50","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1200\/JCO.2016.71.0228","volume":"35","author":"PG Casali","year":"2017","unstructured":"Casali, P. G. et al. Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: Long-term analysis of the european organisation for research and treatment of cancer, Italian sarcoma group, and Australasian gastrointestinal tr. J. Clin. Oncol. 35(15), 1713\u20131720 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"13894_CR51","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1016\/j.clinthera.2016.11.009","volume":"38","author":"J Price","year":"2016","unstructured":"Price, J. What Can Big Data Offer the Pharmacovigilance of Orphan Drugs?. Clin. Ther. 38(12), 2533\u20132545 (2016).","journal-title":"Clin. Ther."},{"issue":"2","key":"13894_CR52","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1365-2125.2006.02746.x","volume":"63","author":"A Blenkinsopp","year":"2007","unstructured":"Blenkinsopp, A., Wilkie, P., Wang, M. & Routledge, P. A. Patient reporting of suspected adverse drug reactions: A review of published literature and international experience. Br. J. Clin. Pharmacol. 63(2), 148\u2013156 (2007).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"13894_CR53","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.chb.2007.01.014","volume":"24","author":"CF van Uden-Kraan","year":"2008","unstructured":"van Uden-Kraan, C. F. et al. Coping with somatic illnesses in online support groups: Do the feared disadvantages actually occur?. Comput. Human Behav. 24(2), 309\u2013324 (2008).","journal-title":"Comput. Human Behav."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13894-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13894-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13894-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T05:50:41Z","timestamp":1669355441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13894-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["13894"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-13894-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]},"assertion":[{"value":"20 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10317"}}